Moonlake Immunotherapeutics Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 4.35% in MoonLake Immunotherapeutics' Class A ordinary shares.
NASDAQ
Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 9.74% of MoonLake Immunotherapeutics' Class A ordinary shares.
NASDAQ
Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 6.25% in MoonLake Immunotherapeutics' Class A ordinary shares.
NASDAQ
Cormorant Asset Management, LP and Bihua Chen have reported a 6.10% beneficial ownership stake in MoonLake Immunotherapeutics' Class A ordinary shares.
NASDAQ
Avoro Capital Advisors LLC and Behzad Aghazadeh reported a 3.15% beneficial ownership stake in MoonLake Immunotherapeutics' Class A Ordinary Shares.
NASDAQ
Deep Track Capital and affiliates have disclosed a passive beneficial ownership of 6.46% in MoonLake Immunotherapeutics' Class A ordinary shares.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an Amendment No. 4 to their Schedule 13G, reporting a 1.1% beneficial ownership in Moonlake Immunotherapeutics' Class A Common Stock as of September 30, 2025.
NASDAQ
Bihua Chen, general partner of Cormorant Asset Management, LP, reported a 3.14% beneficial ownership stake in MoonLake Immunotherapeutics' Class A Ordinary Shares.
NASDAQ
Avoro Capital Advisors and Behzad Aghazadeh have disclosed a 6.5% beneficial ownership stake in MoonLake Immunotherapeutics' Class A Ordinary Shares for investment purposes.
NASDAQ
FMR LLC and Abigail P. Johnson have disclosed a 9.0% beneficial ownership stake in Moonlake Immunotherapeutics' Class A Common Stock as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: T. Rowe Price Associates Discloses 4.7% Passive Stake in MoonLake Immunotherapeutics
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a 4.7% passive beneficial ownership stake in MoonLake Immunotherapeutics as of March 31, 2025.
NASDAQ
T. Rowe Price Associates, Inc. has reported a passive beneficial ownership of 5.3% of MoonLake Immunotherapeutics' common stock as of December 31, 2024.
NASDAQ
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reaffirming their beneficial ownership of 10.0% of MoonLake Immunotherapeutics' Class A Common Stock as of December 31, 2024.